Living with the Endemic
What Does the Medicine Say?
Source: Our World in Data as at 23rd October 2021
The Business of Vaccines
0 Comments
State of the Pandemic - Still Raging, Even Though Everyone is Getting Tired Of It!
Delta has Quietly Changed Public Policy
What the World Needs Next: Market Opportunity
Graphs courtesy of Our World In Data
Recent analyses of populations experiencing further waves of COVID-19 infection based on the Delta variant indicate that new challenges are emerging in the fight against the COVID-19 Pandemic: Some in-use vaccines are failing to provide long-run protection against the rapidly evolving COVID-19 virus, whereas others appear to be showing better long-term performance. See our analysis in our Industry Update 11.
The current situation with vaccines world-wide strongly supports the following hypotheses:
Global Covid Pandemic - Booster shots against the Delta variant
PROTECTION BY VACCINES - is anything better than mRNA?
Does Natural Infection provide better protection against Delta COVID than Vaccination?
Conclusions:
Refana believes that the above data strongly support the following hypotheses:
Appendix Calculation of the comparable protection against breakthrough Delta Infection: Two shots of Pfizer Covid Vaccine vs Recovery from prior natural infection with Covid. Number of Double Vaccinated people in Israel: 5.4 million Number of Recovered people in Israel from Natural Covid Infection: 900,000 Ratio of Double Vaccinated to Recovered: 6:1 (This is the scaling factor of 6)
Global Pandemic
Vaccinations
Industry
Given the broad and extensive coverage by the media and the scientific literature on how the Pharma/Biotech world is doing in the development and deployment of COVID-19 Vaccines in 2020-2021, Refana decided to take an objective, systematic look at the 'current state' of the approved COVID-19 vaccine world, to assess how these vaccines were doing in the fight against the COVID-19 Pandemic. As a result, this 'White Paper' addresses six key questions:
Refana summarized its findings in a short-form outline style to make these insights more accessible. Refana have also provided detailed Appendices with more specific info to support the summary outline, plus a detailed listing of all source links to the original articles and research papers that drove the assessment. This material is not meant to be a detailed scientific review of the approved vaccines, but more of a summary of the ongoing findings related to the approved vaccines with respect to these six key questions, based on the substantial amount of reporting that has been published world-wide during the COVID-19 Pandemic. As such - and as an objective assessment of where things stand - Refana believes this material represents a good consolidated reference document on the current 'State of the Art' for the approved COVID-19 vaccines. Since this is a highly dynamic situation, Refana is referring to this White Paper as the June 2021 Release V1.0. Refana intends to regularly update this material with the latest info on all approved COVID-19 vaccines on a periodic basis. Since this is a highly dynamic situation, Refana is referring to this White Paper as the June 2021 Release V1.0. Refana intends to regularly update this material with the latest info on all approved COVID-19 vaccines on a periodic basis. Global Pandemic
Industry
Global Pandemic
The Business of Vaccines
Medical/ Vaccine Updates
There is a media debate as to whether the pandemic is stabilizing, or whether we are entering a dangerous new 3rd and 4th wave, driven by toxic new mutations to the virus, such as the UK, South African, and Brazilian variants. Refana's view is as follows:
Global Pandemic
Industry and Economics
March has seen warnings of a 4th Wave, emergency use approval for a 1-shot vaccine and an increase in vaccine sales. Volume 6 looks at these headlines and more. Global Pandemic
Industry
Financial news
|